The Biden administration is targeting a system research institutions have relied upon for four decades to force companies developing pharmaceutical drugs to lower the cost of medications. For years, universities were unable to commercialize technology developed with taxpayer money. At the crux of the issue is a public safeguard feature known as march-in rights, meaning the government can take back control of patents if the licensee doesn’t make the product reasonably available to the public.